Cargando…
Evaluation of Activity and Combination Strategies with the Microtubule-Targeting Drug Sagopilone in Breast Cancer Cell Lines
Sagopilone, a fully synthetic epothilone, is a microtubule-stabilizing agent optimized for high in vitro and in vivo activity against a broad range of tumor models, including those resistant to paclitaxel and other systemic treatments. Sagopilone development is accompanied by translational research...
Autores principales: | Eschenbrenner, Julia, Winsel, Sebastian, Hammer, Stefanie, Sommer, Anette, Mittelstaedt, Kevin, Drosch, Michael, Klar, Ulrich, Sachse, Christoph, Hannus, Michael, Seidel, Monika, Weiss, Bertram, Merz, Claudia, Siemeister, Gerhard, Hoffmann, Jens |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Research Foundation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3355879/ https://www.ncbi.nlm.nih.gov/pubmed/22649765 http://dx.doi.org/10.3389/fonc.2011.00044 |
Ejemplares similares
-
Molecular Mode of Action and Role of TP53 in the Sensitivity to the
Novel Epothilone Sagopilone (ZK-EPO) in A549 Non-Small Cell Lung Cancer
Cells
por: Winsel, Sebastian, et al.
Publicado: (2011) -
Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma
por: DeConti, R C, et al.
Publicado: (2010) -
Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer
por: McMeekin, S, et al.
Publicado: (2012) -
Weekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial
por: Arnold, D, et al.
Publicado: (2009) -
Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group
por: Stupp, R., et al.
Publicado: (2011)